Ad
related to: depakote information for patients with dementia diagnosis
Search results
Results from the WOW.Com Content Network
Valproate may cause increased somnolence in the elderly. In a trial of valproate in elderly patients with dementia, a significantly higher portion of valproate patients had somnolence compared to placebo. In approximately one-half of such patients, there was associated reduced nutritional intake and weight loss. [4]
Depakote (valproic acid/sodium valproate) – an antiepileptic and mood stabilizer used to treat bipolar disorder, neuropathic pain and others; sometimes called an antimanic medication. Depakene is the trade name for the same drug prepared without sodium. Desyrel – an atypical antidepressant used to treat depression and insomnia
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress.. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication.
Dementia is a devastating disease that impacts one in 10 older Americans. But while many people want to avoid developing dementia, the exact causes of the condition have remained largely a mystery ...
The average time before a patient moved to a nursing home after diagnosis was 3.3 years. Some 13% of people moved to a nursing home in the year after their diagnosis. This increased to 57% after ...
Definite Alzheimer's disease: The patient meets the criteria for probable Alzheimer's disease and has histopathologic evidence of AD via autopsy or biopsy. Probable Alzheimer's disease: Dementia has been established by clinical and neuropsychological examination. Cognitive impairments also have to be progressive and be present in two or more ...
Using data from a long-term U.S. survey, it found that newly diagnosed dementia patients are far more likely to act, noting that 25% of respondents sought financial help from children, compared to ...
The company misbranded Depakote by promoting the drug to control agitation and aggression in elderly dementia patients and to treat schizophrenia when neither of these uses was FDA approved. This settlement figure represents resolution of other claims in addition to off-label promotion. [38]
Ad
related to: depakote information for patients with dementia diagnosis